Side-by-side · Research reference
DermorphinvsLiraglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED20/47 cited
BFDA-ApprovedFlagship14/45 cited
Dermorphin
Opioid Peptide · μ-Receptor Agonist · Research Only
Research only · ICV / SC (animal models)
Liraglutide
Daily GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once daily
01Mechanism of Action
Parameter
Dermorphin
Liraglutide
Primary target
μ-opioid receptors (central and peripheral)Negri 1992Steel 2014
GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014
Pathway
μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization
GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014Marso 2016
Downstream effect
Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects
Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016
Feedback intact?
N/A — exogenous opioid agonist
Glucose-dependent insulin release preserves physiological feedback
Origin
Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998Mignogna 1992
Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014
02Dosage Protocols
Parameter
Dermorphin
Liraglutide
Legal status
Controlled substance in many jurisdictions · Research only
Not approved for human use.
—
Animal research (ICV)
Low nanomolar to picomolar range
Intracerebroventricular administration in rodent models.
—
Detection limit (doping)
5 pg/mL in equine plasma/urineSteel 2014
High-throughput LC-MS/MS screen developed for racing industry.
—
Duration of action
10–120 minutes (dose-dependent, intrathecal)
—
Evidence basis
Animal studies · In vitro assays
FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016SAXENDA (liraglutide) injectio 2014
Human toxicity
Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025
—
Standard dose (weight, Saxenda)
—
3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014
Frequency
—
Once daily, same time each day
Titration schedule
—
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Mitigates GI side effects.
Duration
—
Indefinite for chronic indication
Reconstitution
—
Pre-filled commercial pen (no reconstitution)
Timing
—
Any time of day; consistent
04Side Effects & Safety
Parameter
Dermorphin
Liraglutide
Opioid effects
Respiratory depression, sedation, euphoria, tolerance, dependence risk
—
Kambô ritual toxicity
Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025
—
Receptor selectivity caveat
Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992
—
Proteolytic stability
Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996
—
GI symptoms
—
Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014
Pancreatitis risk
—
Rare; discontinue if suspected
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014
Hypoglycemia
—
Low risk as monotherapy; elevated with sulfonylureas / insulin
Heart rate
—
Modest ↑ resting HR (~2-3 bpm)
Pregnancy / OB
—
Contraindicated
Absolute Contraindications
Dermorphin
- ·Human use — not approved by any regulatory authority
- ·Controlled substance status — possession illegal in many jurisdictions
- ·Known opioid hypersensitivity or respiratory compromise
Liraglutide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to liraglutide
Relative Contraindications
Dermorphin
- ·Any context outside approved animal research protocols
- ·CNS depressant co-administration
Liraglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe gastrointestinal disease
05Administration Protocol
Parameter
Dermorphin
Liraglutide
1. Legal and ethical framework
Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.
Commercial pre-filled pen, no reconstitution required.
2. Animal research protocols
In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Analytical detection
High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014
Once daily, same time each day. Take with or without food.
4. Kambô ritual (traditional use)
Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025
Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.
5. Needle
—
Pen-supplied 32G needle.